JP2015517511A5 - - Google Patents

Download PDF

Info

Publication number
JP2015517511A5
JP2015517511A5 JP2015512051A JP2015512051A JP2015517511A5 JP 2015517511 A5 JP2015517511 A5 JP 2015517511A5 JP 2015512051 A JP2015512051 A JP 2015512051A JP 2015512051 A JP2015512051 A JP 2015512051A JP 2015517511 A5 JP2015517511 A5 JP 2015517511A5
Authority
JP
Japan
Prior art keywords
antibody
kit
seq
lymphoma
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015512051A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015517511A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/060098 external-priority patent/WO2013171287A1/en
Publication of JP2015517511A publication Critical patent/JP2015517511A/ja
Publication of JP2015517511A5 publication Critical patent/JP2015517511A5/ja
Pending legal-status Critical Current

Links

JP2015512051A 2012-05-16 2013-05-15 Ｃｄ３７抗体とｉｃｅ（イフォスファミド、カルボプラチン、エトポシド）の併用 Pending JP2015517511A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12168398 2012-05-16
EP12168398.1 2012-05-16
PCT/EP2013/060098 WO2013171287A1 (en) 2012-05-16 2013-05-15 Combination of cd37 antibodies with ice (ifosfamide, carboplatin, etoposide)

Publications (2)

Publication Number Publication Date
JP2015517511A JP2015517511A (ja) 2015-06-22
JP2015517511A5 true JP2015517511A5 (enExample) 2016-06-30

Family

ID=48463997

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015512051A Pending JP2015517511A (ja) 2012-05-16 2013-05-15 Ｃｄ３７抗体とｉｃｅ（イフォスファミド、カルボプラチン、エトポシド）の併用

Country Status (4)

Country Link
US (1) US8992915B2 (enExample)
EP (1) EP2849784A1 (enExample)
JP (1) JP2015517511A (enExample)
WO (1) WO2013171287A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20090499A1 (es) * 2007-08-09 2009-05-18 Boehringer Ingelheim Int Anticuerpos anti-cd37
CA2771403C (en) 2009-08-19 2015-02-24 Eisai R&D Management Co. Ltd. Quinoline derivative-containing pharmaceutical composition
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
EP3187491A4 (en) 2014-08-28 2018-08-01 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
US20180028662A1 (en) 2015-02-25 2018-02-01 Eisai R&D Management Co., Ltd. Method for Suppressing Bitterness of Quinoline Derivative
KR20240064733A (ko) 2015-03-04 2024-05-13 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
CA2988707C (en) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
CN108135894B (zh) 2015-08-20 2021-02-19 卫材R&D管理有限公司 肿瘤治疗剂
CN110072528B (zh) 2017-02-08 2022-04-26 卫材R&D管理有限公司 治疗肿瘤的药物组合物
CN119285787A (zh) 2017-03-31 2025-01-10 健玛保控股有限公司 双特异性抗cd37抗体、单克隆抗cd37抗体及其使用方法
WO2018212202A1 (en) 2017-05-16 2018-11-22 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8800077D0 (en) 1988-01-05 1988-02-10 Ciba Geigy Ag Novel chimeric antibodies
ES2146572T3 (es) 1988-09-06 2000-08-16 Xoma Technology Ltd Elementos de expresion genica y la produccion de anticuerpos quimericos de raton-ser humano.
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
EP0563475B1 (en) 1992-03-25 2000-05-31 Immunogen Inc Cell binding agent conjugates of derivatives of CC-1065
DE19911329A1 (de) 1998-03-27 2000-09-21 Benes Ivan Friedrich Humantherapeutisch anwendbares Radioimmunkonjugat und Verfahren zu seiner Herstellung
HK1049997B (en) 1999-11-24 2007-02-23 Immunogen, Inc. Cytotoxic agents comprising taxanes and their therapeutic use
AU767394C (en) 1999-12-29 2005-04-21 Immunogen, Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
WO2004016753A2 (en) * 2002-08-15 2004-02-26 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
CA2476166C (en) 2002-02-14 2011-11-15 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
US6756397B2 (en) 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
US6596757B1 (en) 2002-05-14 2003-07-22 Immunogen Inc. Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use
KR20060080535A (ko) 2003-05-14 2006-07-10 이뮤노젠 아이엔씨 약물 콘쥬게이트 조성물
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
AU2006272555B2 (en) 2005-07-25 2012-03-08 Aptevo Research And Development Llc B-cell reduction using CD37-specific and CD20-specific binding molecules
DK1931709T3 (en) 2005-10-03 2017-03-13 Xencor Inc FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
EP1806365A1 (en) 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
WO2009023386A2 (en) 2007-07-06 2009-02-19 Trubion Pharmaceuticals, Inc. Binding peptides having a c-terminally disposed specific binding domain
PE20090499A1 (es) 2007-08-09 2009-05-18 Boehringer Ingelheim Int Anticuerpos anti-cd37
NZ603059A (en) * 2008-04-11 2014-07-25 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
CN102159243B (zh) * 2008-07-21 2015-08-19 免疫医疗公司 用于改良的治疗特征的抗体的结构变体
AU2009313877A1 (en) * 2008-11-13 2011-06-30 Emergent Product Development Seattle, Llc CD37 immunotherapeutic combination therapies and uses thereof
US20120189618A1 (en) * 2010-07-16 2012-07-26 Boehringer Ingelheim International Gmbh Superior efficacy of cd37 antibodies in cll blood samples
WO2013160396A1 (en) 2012-04-26 2013-10-31 Boehringer Ingelheim International Gmbh Combination of cd37 antibodies with bendamustine
WO2013171289A1 (en) 2012-05-16 2013-11-21 Boehringer Ingelheim International Gmbh Combination of cd37 antibodies with further agents

Similar Documents

Publication Publication Date Title
Melamed et al. Multiple sclerosis and cancer: the ying-yang effect of disease modifying therapies
CN111065411B (zh) Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途
JP2019517549A5 (enExample)
JP2017507954A5 (enExample)
TWI818120B (zh) 藉由免疫檢查點阻礙藥與ｆｏｌｆｉｒｉｎｏｘ療法之併用的癌症治療
JP2021138750A (ja) 腫瘍性疾患のための治療
JP2015517512A5 (enExample)
JP2010529026A5 (enExample)
JP2015516980A5 (enExample)
WO2019072220A1 (zh) Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途
CN114224889A (zh) 西奥罗尼联合免疫检查点抑制剂在抗肿瘤治疗中的应用
US20180319861A1 (en) Combination therapy for malignant diseases
JP2023536655A5 (enExample)
JP2017537927A5 (enExample)
KR20240117655A (ko) 항-cd19 항체 및 베네토클락스 조합 치료에 대한 치료 패러다임
JP2013511975A5 (enExample)
CN111166878B (zh) 靶向肿瘤抗原的抗体与iNKT细胞的组合的制备方法与用途
AU2014227019A1 (en) Novel peptide having 5 linked CTL epitopes
JP2018522881A5 (enExample)
TW201834650A (zh) 哺乳類雷帕黴素靶蛋白抑制劑及氯喹於治療癌症之用途
JP7504106B2 (ja) がんの処置のための組合せ物
JP2024516970A5 (enExample)
JP2015500836A5 (enExample)
US20250114456A1 (en) Enhanced immunotherapeutic method comprising combined administration of photodynamic / radiotherapeutic compounds and immunotherapeutic agents
US20250381190A1 (en) Therapeutic combinations of capivasertib and venetoclax